8.00

1.27% 0.10

Puma Biotechnology Inc (PBYI)

Overview News Price History Option Chain Financials Discussions Forecast

Puma Biotechnology Inc stock is traded at $8.00, with a volume of 342.26K. It is up +1.27% in the last 24 hours and up +13.96% over the past month. Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Previous Close:

$7.90

Open:

$7.9

24h Volume:

342.26K

Relative Volume:

1.15

Market Cap:

$407.20M

Revenue:

$227.18M

Net Income/Loss:

$24.38M

P/E Ratio:

16.76

EPS:

0.4774

Net Cash Flow:

$53.60M

1W Performance:

-3.15%

1M Performance:

+13.96%

6M Performance:

+30.93%

1Y Performance:

+127.27%

1-Day Range:

$7.70

$8.135

1-Week Range:

$7.67

$8.44

52-Week Range:

$3.03

$8.44

Puma Biotechnology Inc Stock (PBYI) Company Profile

Name

Puma Biotechnology Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(424) 248-6500

Address

10880 WILSHIRE BLVD., LOS ANGELES, CA

Employee

179

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

PBYI's Discussions on Twitter

Compare PBYI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PBYI Puma Biotechnology Inc	8.00	407.20M	227.18M	24.38M	53.60M	0.4774
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy
Jun-25-20	Resumed	BofA/Merrill	Underperform
Oct-08-19	Downgrade	Goldman	Neutral → Sell
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-10-19	Downgrade	Citigroup	Buy → Neutral
Jan-17-19	Initiated	Leerink Partners	Mkt Perform
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Sep-17-18	Initiated	Goldman	Sell
May-11-18	Reiterated	Stifel	Buy
Nov-10-17	Reiterated	Citigroup	Buy
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform
Oct-02-17	Reiterated	Stifel	Buy
Sep-11-17	Reiterated	Credit Suisse	Outperform
Jul-10-17	Resumed	Leerink Partners	Outperform
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform
Mar-02-17	Reiterated	RBC Capital Mkts	Sector Perform

View All

Puma Biotechnology Inc Stock (PBYI) Latest News

Jul 08, 2026

Puma Biotechnology’s Douglas M. Hunt sells $69,904 in shares By Investing.com - Investing.com Nigeria

Jul 08, 2026

Puma biotechnology CFO Maximo Nougues sells $77,556 in stock By Investing.com - Investing.com South Africa

Jul 08, 2026

Form 4 Puma Biotechnology Inc For: 8 July By Investing.com - Investing.com Nigeria

Jul 08, 2026

Alan Auerbach, Puma Biotechnology president and CEO, sells $364,051 By Investing.com - Investing.com Nigeria

Jul 08, 2026

Puma Biotechnology (PBYI) CEO sells 44,058 shares under 10b5-1 plan - Stock Titan

Jul 08, 2026

Puma Biotechnology (PBYI) CFO sells 9,386 shares in 10b5-1 trade - Stock Titan

Jul 08, 2026

Puma Biotechnology’s Douglas M. Hunt sells $69,904 in shares - Investing.com

Jul 08, 2026

Jul 06, 2026

Form 144 PUMA BIOTECHNOLOGY For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026

Puma Biotechnology highlights targeted cancer therapies as investors watch Nasdaq-listed PBYI - ad-hoc-news.de

Jul 03, 2026

Jul 02, 2026

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 - BioSpace

Jul 02, 2026

PBYI News | PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) - ChartMill

Jul 02, 2026

Jun 29, 2026

Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Enterprise value to revenue forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView

Jun 28, 2026

Enterprise value to EBITDA forward of Puma Biotechnology Inc – NASDAQ:PBYI - TradingView

Jun 28, 2026

PBYI Forecast — Price Target — Prediction for 2027 - TradingView

Jun 28, 2026

Price to book forward of Puma Biotechnology Inc – NASDAQ:PBYI - TradingView

Jun 28, 2026

Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 3000 Growth Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Price to sales forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView

Jun 27, 2026

Enterprise value to EBIT forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView

Jun 27, 2026

Enterprise value to EBITDA forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView

Jun 27, 2026

Jun 26, 2026

Puma Biotechnology, Inc. Actuals & Estimates (NASDAQ:PBYI) - TradingView

Jun 26, 2026

Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates - Kavout | AI

Jun 26, 2026

Jun 24, 2026

Puma Pharmaceuticals Puma Biotechnology Puma Biotechnology Puma 2019 Revenue Breast Cancer Treatment - consumerthai

Jun 24, 2026